期刊
GENES
卷 13, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/genes13071213
关键词
G protein-coupled receptor; DNA methylation; biomarker; drug sensitivity
资金
- National Natural Science Foundation of China [U20A20376, 61972116, 62102120]
- Applied Technology Research and Development Project of Heilongjiang [GA20C018]
- Heilongjiang Postdoctoral Fund [LBH-Z20158]
Tumor heterogeneity poses challenges for cancer diagnosis and treatment. This study proposes a computational method to quantify the specificity of GPCRs DNA methylation and identifies specific GPCRs DNA methylation biomarkers. Potential drugs were discovered through predicting drug sensitivities. Specific biomarkers were validated in various cancers.
Tumor heterogeneity presents challenges for personalized diagnosis and treatment of cancer. The identification method of cancer-specific biomarkers has important applications for the diagnosis and treatment of cancer types. In this study, we analyzed the pan-cancer DNA methylation data from TCGA and GEO, and proposed a computational method to quantify the degree of specificity based on the level of DNA methylation of G protein-coupled receptor-related genes (GPCRs-related genes) and to identify specific GPCRs DNA methylation biomarkers (GRSDMs) in pan-cancer. Then, a ridge regression-based method was used to discover potential drugs through predicting the drug sensitivities of cancer samples. Finally, we predicted and verified 8 GRSDMs in adrenocortical carcinoma (ACC), rectum adenocarcinoma (READ), uveal Melanoma (UVM), thyroid carcinoma (THCA), and predicted 4 GRSDMs (F2RL3, DGKB, GRK5, PIK3R6) which were sensitive to 12 potential drugs. Our research provided a novel approach for the personalized diagnosis of cancer and informed individualized treatment decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据